Imunon, Inc. (IMNN) is a leading venture in the biotechnology industry that is fundamentally dedicated to improving human health through the discovery, development, and commercialization of groundbreaking therapies. The company possesses a strong reputation for its undeterred commitment to innovation that aligns with the ultimate goal of treating diseases which have so far remained largely untreatable.
Imunon, Inc. has successfully established a comprehensive and diverse portfolio of therapies focused mainly in the fields of oncology, infectious diseases, autoimmune diseases, and neuroscience. The company blockchains all the processes of drug discovery and development; from target identification, validation, and lead optimization, to product manufacturing, regulatory filing, and clinical studies.
Driven by a team of highly skilled scientists, medical professionals and business leaders, Imunon, Inc. leverages the latest advancements in immunology and genetic research to elucidate disease pathways and to identify novel therapeutic agents. The company is consistently at the forefront of biotechnological research, working to seek out solutions that combat severe illness and optimize patient health outcomes.
One of the standout facets of Imunon, Inc. is its unique approach towards collaboration with external scientists, clinicians, and healthcare professionals. It believes in harnessing the power of shared expertise and knowledge to expedite the progress of developing critical therapies. Such collaborative efforts have resulted in heightened insights and broader perspectives, providing a decisive edge in the race towards breakthrough therapies.
Relentlessly striving to challenge, improve, and disrupt, Imunon, Inc. has an evident history of developing and delivering innovative therapies that have profound transformative potential. Their work to date has resulted in significant strides being made towards ultimately eradicating diseases that threaten human health across the globe.
Looking towards the future, Imunon, Inc. aims to utilize its scientific expertise, robust pipeline, and dedicated team to continue making a substantial contribution to global healthcare. The company's commitment to improving public health, combined with its innovative approach to tackling complex diseases, render Imunon, Inc. a force to be reckoned with in the world of biotechnology.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
IMUNON, Inc. announced that its Independent Data Monitoring Committee (IDMC) has recommended the continued development of IMNN-001 in its Phase 2 minimal residual disease (MRD) study. The recommendation follows a favorable safety review, noting no new safety signals or severe adverse events, reinforcing the therapy's differentiated safety profile as an IL-12-based immunotherapy. This decision supports the ongoing pivotal Phase 3 OVATION 3 trial, especially after encouraging preliminary data from the MRD study suggested deeper anti-tumor activity and immune activation.
Imunon (NASDAQ: IMNN) awarded Executive Chairman Michael H. Tardugno 5,824 shares at a price of $1.47 per share on September 11, 2026. This transaction increased his total holdings in the company to 95,699 shares, representing approximately 6.1% of his overall ownership post-award. The filing provides transparent details about the award price and the executive's updated stake.
IMUNON, Inc. has entered a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to advance clinical development of its IL-12 DNA plasmid-based immunotherapy, IMNN-001. Under the agreement, NCI's Cancer Therapy Evaluation Program will assume regulatory sponsorship and evaluate IMNN-001 in new solid tumor indications and combination regimens, while IMUNON retains intellectual property. This collaboration allows IMUNON to expand the drug's application beyond ovarian cancer without diverting resources from its ongoing Phase III OVATION 3 trial.